Markets
BSE See NSE See 33,359.90
17.10 (0.05%)
collapse Related Readings collapse

New Land Acquisition Act Comes Into Force From January 1, 2014

By Saikat Mitra | 1/1/2014 2:41 PM Wednesday

The Indian economy has been growing at the slowest pace in a decade, and one of the reasons for this is the slowdown in the investment cycle. What could accentuate this slacked pace in the new year is the Land Acquisition Act, which comes into force from January 1, 2014. The bill was passed in the Monsoon session of Parliament in 2013 and on September 27, it received assent of the President of India, Pranab Mukherjee.

This new legislation replaces the 120-year old one and was framed with the intention of providing compensation to farmers in a fair and just manner. The salient feature of this Act is that it requires atleast 70% of the people whose land is being acquired to give consent for Public-Private Partnerships. This becomes 80% when the land is being acquired by any private player. Also notable is the fact that the compensation has been upped up to four times the market values in rural areas and twice the market value in urban areas.

Another key feature of the Act is that has been introduced with retrospective effect to provide justice in historical cases where no reward for land acquisition has been made. Moreover, if the land is being sold to a third party and the profits are more than 40%, these profits should be shared with the land owner.  A maximum of 5% irrigated, multi-cropped land may be acquired in a single district.

Although these clauses ensure fair and just compensation for farmers, the flipside is that land acquisition will become dearer for the companies. This means that project costs will remain on the higher side and many projects may become financially unviable. The power and realty sectors will be mainly affected.

 

Find More Articles on: Economy, Markets, DSIJ Mindshare

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

Mangalam Drugs posts 31 per cent growth in profit, stock surges

Mangalam Drugs posts 31 per cent growth in profit, stock surges

Pharma company Mangalam Drugs & Organics' stock rallied on Monday as the company announced its second quarter results for the financial year 2018.

Private banks spike up

Private banks spike up

In an otherwise lacklustre trading session, private banks rallied on Monday. Yes Bank, IndusInd Bank and Kotak Bank were trading higher.

 

Biocon surges 6 per cent on EIR from USFDA

Biocon surges 6 per cent on EIR from USFDA

Pharma company Biocon shot up by over 6 per cent in early trade on Monday as the company received the EIR from the USFDA.

GST illuminates logistic earnings

GST illuminates logistic earnings

The sector is reaping benefits of GST regime now, as we can observe from the earnings. GST implementation has changed the industry aspects and tax structure which aided the overall growth of the companies.

Strides Shasun and Eris Lifesciences surge post acquisition deal

Strides Shasun and Eris Lifesciences surge post acquisition deal

The Indian brand business of Strides Shasun is acquired by Eris Lifesciences for a cash consideration of Rs 500 crore. The company informed the stock exchanges through a filing on Monday.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.25 p.m. on November 20.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on November 20 opened up. BSE Sensex is trading at 33,349.14, up by 6.34 points and the Nifty is trading at 10,283.20, down by 0.40 points.

Glenmark Pharma up by 2 per cent on USFDA nod for Hailey 24

Glenmark Pharma up by 2  per cent  on USFDA nod for Hailey 24

Pharma major, Glenmark Pharmaceuticals received the final nod of USFDA for Hailey 24 Fe. The stock of the company surged by over 2 per cent in the intraday trade on Monday.

Cipla gets final approval for generic Dacogen

Cipla gets final approval for generic Dacogen

Pharma major, Cipla has announced that it has received final ANDA approval for decitabine injection 50 mg vial from the USFDA.

 

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.03 lakh contracts with a turnover of Rs. 5,33,783.20 crore.